Artelo Biosciences to Present at Sequire Biotechnology Conference on February 2nd
27 January 2023 - 12:30AM
Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage
pharmaceutical company focused on modulating lipid-signaling
pathways to develop treatments for people living with cancer, pain,
and neurological conditions, announced today that Gregory D.
Gorgas, Chief Executive Officer of Artelo, will be presenting
virtually at the Sequire Biotechnology Conference. Mr. Gorgas plans
to discuss the latest developments related to the Company’s ongoing
Cancer Appetite Recovery Study (CAReS).
Presentation details: |
Event: Artelo’s Presentation at the Sequire
Biotechnology Conference |
Date: Thursday, February 2, 2023 |
Time: 1:00 PM Eastern Time |
Register to watch the presentation at:
https://biotech.sequireevents.com/.
Summary of Sequire Biotechnology Conference
Expected to reach over $727 billion by 2025, the Biotechnology
industry is showing consistent growth with over 6,500 biotech
companies within the US and over 20,000 worldwide This one-day
virtual investor event, highlighting public companies in the
biotechnology space, will be held via SRAX’s Sequire Virtual Events
platform. Thousands of active biotechnology investors have been
invited to the event, which will feature several biotechnology
focused companies hosting 25 minute presentations, alongside
keynotes highlighting prominent names in this space.
About Artelo Biosciences
Artelo Biosciences, Inc. is a clinical-stage pharmaceutical
company focused on modulating lipid-signaling pathways to develop
treatments for people living with cancer, pain, and neurological
conditions. Artelo is advancing a portfolio of broadly applicable
product candidates designed to address significant unmet needs in
multiple diseases and conditions, including anorexia, cancer, PTSD,
pain, and inflammation. Led by proven pharmaceutical executives
collaborating with highly respected researchers and technology
experts, Artelo applies leading edge scientific, regulatory, and
commercial discipline to develop high-impact therapies. More
information is available at www.artelobio.com and
Twitter: @ArteloBio.
Forward Looking Statements
This press release contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934 and Private Securities Litigation Reform Act, as
amended, including those relating to Artelo’s product development,
clinical and regulatory timelines, market opportunity, competitive
position, possible or assumed future results of operations,
business strategies, potential growth opportunities and other
statement that are predictive in nature. These forward-looking
statements are based on current expectations, estimates, forecasts
and projections about the industry and markets in which we operate
and management’s current beliefs and assumptions. These statements
may be identified by the use of forward-looking expressions,
including, but not limited to, “expect,” “anticipate,” “intend,”
“plan,” “believe,” “estimate,” “potential,” “predict,” “project,”
“should,” “would” and similar expressions and the negatives of
those terms. These statements relate to future events or our
financial performance and involve known and unknown risks,
uncertainties, and other factors which may cause actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements. Such factors include those set
forth in Artelo’s filings with the Securities and Exchange
Commission, including our ability to raise additional capital in
the future. Prospective investors are cautioned not to place undue
reliance on such forward-looking statements, which speak only as of
the date of this press release. Artelo undertakes no obligation to
publicly update any forward-looking statement, whether as a result
of new information, future events or otherwise, except to the
extent required by applicable securities laws.
Investor Relations
Contact:Crescendo Communications, LLCTel:
212-671-1020Email: ARTL@crescendo-ir.com
Artelo Biosciences (NASDAQ:ARTL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Artelo Biosciences (NASDAQ:ARTL)
Historical Stock Chart
From Apr 2023 to Apr 2024